Table 1.
Characteristics | Training Set (N = 109) | Validation Set (N = 47) | P |
---|---|---|---|
Gender (Male/ Female) | 59/50 | 29/18 | 0.25 |
Age (Mean ± SD) | 53.2 ± 12.4 | 55.4 ± 10.6 | 0.29 |
Preoperative AFP (Mean ± SD) (ng/mL) | 946.7 ± 50,371.4 | 7891.4 ± 3530.9 | 1.00 |
Cirrhosis (positive/negative) | 67/42 | 28/19 | 0.82 |
Hepatitis (positive/negative) | 96/13 | 42/5 | 0.82 |
Number of nodules (1/≥2) | 87/22 | 33/14 | 0.35 |
Lesion diameter (Mean ± SD) (cm) | 4.2 ± 2.9 | 3.9 ± 3.3 | 0.57 |
Treatment method (resection/ablation) | 33/76 | 18/29 | 0.15 |
ER (%) | 50/109(45.9) | 25/47(53.2) | 0.51 |
PT-E positive rate (%) | 23/109 (21%) | 16/47 (34%) | 0.13 |
T-RO risk score (mean ± SD) | 0.46 ± 0.28 | 0.43 ± 0.36 | 0.58 |
PT-RO risk score (mean ± SD) | 0.46 ± 0.26 | 0.44 ± 0.29 | 0.67 |
SD standard deviation, AFP alpha-fetoprotein. Hepatitis, Hepatitis B or C; ER early recurrence, PT-E peritumoral enhancement, T-RO tumoral radiomics, PT-RO peritumoral radiomics, T-RO risk score refers to the application of T-RO model to the image of the cases in the training and validation sets, and obtain the risk score of each case (the output is the specific value, 0–1). PT-RO risk score refers to the application of PT-RO model to the image of the cases in the training and validation sets, and obtain the risk score of each case (the output is the specific value, 0–1). P-value reflected the differences between the training and validation cohorts, and P values of less than 0.05 (two-sided) were considered statistically significant